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A B S T R A C TObjectives: The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a
psychometrically validated patient-reported outcome measure
increasingly used in trials of treatments for multiple sclerosis. How-
ever, it is non–preference-based and not amenable for use across
policy decision-making contexts. Our objective was to statistically
map from the MSIS-29, version 2, to the EuroQol five-dimension (EQ-
5D) and the six-dimension health state short form (derived from short
form 36 health survey) (SF-6D) to estimate algorithms for use in cost-
effectiveness analyses. Methods: The relationships between MSIS-29,
version 2, and EQ-5D and SF-6D scores were estimated by using data
from a cohort of people with multiple sclerosis in South West England
(n ¼ 672). Six ordinary least squares (OLS), Tobit, and censored least
adjusted deviation (CLAD) regression analyses were conducted on
estimation samples, including the use of subscale and item scores,
squared and interaction terms, and demographics. Algorithms from
models with the smallest estimation errors (mean absolute error
[MAE], root mean square error [RMSE], normalized RMSE) were then
assessed by using separate validation samples. Results: Tobit andnt matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.07.007
wton@pms.ac.uk.
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, Veysey Building, Salmon Pool Lane, Exeter, DevoCLAD. For the EQ-5D, the OLS models including subscale squared
terms, and item scores and demographics performed comparably
(MAE 0.147, RMSE 0.202 and MAE 0.147, RMSE 0.203, respectively), and
estimated scores well up to 3 years post-baseline. Estimation errors
for the SF-6D were smaller (OLS model including squared terms: MAE
0.058, RMSE 0.073; OLS model using item scores and demographics:
MAE 0.059, RMSE 0.08), and the errors for poorer health states found
with the EQ-5D were less pronounced. Conclusions: We have pro-
vided algorithms for the estimation of health state utility values, both
the EQ-5D and SF-6D, from scores on the MSIS-29, version 2. Further
research is now needed to determine how these algorithms perform
in practical decision-making contexts, when compared with observed
EQ-5D and SF-6D values.
Keywords: cost-effectiveness, decision making, multiple sclerosis,
Quality of life.
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The use of clinical tools, such as the Expanded Disability Status
Scale (EDSS) [1], for the assessment of the impact of multiple
sclerosis (MS) can describe symptoms, functional disability, and
disease progression, but such measures are not able to capture
the full impact of MS on people’s lives, particularly in terms of
their health-related quality of life (HRQOL) [2]. Over recent years,
internationally [3], across disease groups [4], and specifically in
the field of MS [2,5], there has been a move toward the use of
patient-reported outcome measures, which aim to encapsulate
these broader effects.
The 29-item Multiple Sclerosis Impact Scale (MSIS-29) [6,7]
was specifically constructed to assess the impact of MS on
people’s HRQOL in terms of their physical and psychologicalwell-being. The measure is founded on qualitative interviews
with people with MS and has been developed by using both
traditional [8] and contemporary [7,9] psychometric techniques.
Its flexibility for use in different settings (e.g., hospital and
community) has been demonstrated [10], it can be completed
by proxies [11], it has been shown to be responsive over time
[2,12,13], and a minimally important difference has been sug-
gested for its physical subscale [12]. The MSIS-29 is now in its
second version [7] and given its strong foundations as a suitable
outcome measure for clinical trials of the effectiveness of treat-
ments for MS, it is being increasingly used.
However, health policy decision makers also increasingly
need information on the comparative effectiveness and cost-
effectiveness of treatments across different disease groups. In its
current form, the MSIS-29 is not amenable for use in this way,for Pharmacoeconomics and Outcomes Research (ISPOR).
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VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 8 4 – 1 0 9 1 1085because it is not a preference-based measure [14]. Preference-
based measures use preference data, often elicited from general
populations, to assign relative values to health state descriptions.
Preference-based measures have two components: 1) a means of
describing health status and 2) a mechanism for assigning health
state utility values to each of the possible health states [15]. The
health state utility values can be derived by a variety of methods
and give values on a scale where 1 is equivalent to full health and
0 is equivalent to death. Data from preference-based measures
are more amenable for use in health policy decision making,
because preferences for the health states or outcomes associated
with interventions can be compared across different conditions.
Preference-based responses are also used to estimate quality-
adjusted life-years (QALYs).
QALYs combine quantity and quality of life in a single
measure of health outcome, by adjusting life-years survived
using a quality-of-life weight, with the weight usually being
health state utility values derived from preference data [15]. For
example, a year in full health would equate to 1 QALY, and 2 years
in ‘‘half health’’ (0.5 health state value) would also equate to 1
QALY. QALYs are the outcome of choice in a growing number of
health policy settings [16–18].
When an outcome measure, such as the MSIS-29, is not
preference based, one solution to enable it to be used in
comparative effectiveness and cost-effectiveness analyses is to
statistically ‘‘map’’ it to a commonly used preference-based
measure [19] such as the EuroQol five-dimension (EQ-5D) [20,21]
or the six-dimension health state short form (derived from the
short form 36 health survey [SF-36] and the short form 12 health
survey [SF-12]) (SF-6D) [22,23]. In mapping studies, statistical
regression analyses are used to map from a ‘‘starting’’ measure
(e.g., the MSIS-29) to a ‘‘target’’ measure (e.g., the EQ-5D). The
relationship between the measures is estimated, and algorithms
of this relationship are derived. These algorithms can then be
used with other data to convert non–preference-based measure
scores (e.g., the MSIS-29) to preference-based measure scores
(e.g., the EQ-5D).
‘‘Mapping’’ has become a fairly common approach and has
been conducted in a wide range of disease areas, for example, in
osteoarthritis [24], cancer [25], Crohn’s disease [26], and oral
health [27]. Yet, the approach has been less used with neurolo-
gical conditions.
Over the last decade, a number of new medicines have been
licensed for the treatment of MS, but the evaluation of these
medicines has been hampered by an absence of good quality data
on the costs and, particularly, the benefits of these treatments
[28]. This article estimates and tests mapping algorithms to
convert MSIS-29, version 2 (v2), scores to EQ-5D and SF-6D health
state utility values for use in assessing the comparative effec-
tiveness and cost-effectiveness of treatments for people with MS.Methods
The Data
Data from the UK South West Impact of Multiple Sclerosis
(SWIMS) cohort were used for analysis. SWIMS is a longitudinal,
prospective, cohort study of people with MS in Devon and Corn-
wall (South West England), with individuals followed-up every
6 months [29]. Data are collected on demographics and clinical
features and across a range of patient-reported outcomes,
including the MSIS-29 v2, the EQ-5D, and the SF-36. SWIMS
commenced recruitment in August 2004, and all participants
who had completed baseline questionnaires including complete
MSIS-29 v2, the EQ-5D, the SF-36, and demographic (age and
gender) data by February 2010 were included in this analysis.The SWIMS study was approved in the United Kingdom by the
Cornwall and Plymouth and South Devon Research Ethics Com-
mittees, and written informed consent was obtained from all
participants.
Measures
MSIS-29 v2 [6,7]
The MSIS-29 is a 29 item, condition-specific, self-report ques-
tionnaire for measuring the impact of MS on people’s lives. It has
two subscales: a 20-item physical impact scale and a 9-item
psychological impact scale (and no total score). It is currently in
its second version, which has four-point response categories for
each item: ‘‘not at all,’’ ‘‘a little,’’ ‘‘moderately,’’ and ‘‘extremely.’’
Scores on the physical impact scale can range from 20 to 80 and
on the psychological impact scale from 9 to 36, with lower scores
indicating little impact of MS and higher scores indicating greater
impact.
The EQ-5D [20]
The EQ-5D is a generic health status measure comprising five
subscales (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression), with each subscale having three
response levels (1, ‘‘no problems’’; 2, ‘‘moderate problems’’; 3,
‘‘severe problems’’). This classification of health status results in
243 possible health state descriptions.
Participant responses to the EQ-5D can be converted to the
EQ-5D derived single index, a generic preference-based measure,
using preference weights for the health states. For example, in
the United Kingdom, values that have been derived from the
preferences of a general population sample for each of the 243
possible health states are commonly used [21]. This gives values
for each of the EQ-5D health states on an index ranging from 1.00
for the best health state to  0.594 for the worst health state. The
EQ-5D is frequently used in clinical studies and cost-
effectiveness analyses, and it is currently the measure preferred
by the UK National Institute of Health and Clinical Excellence in
its health technology appraisals process [16].
SF-36/SF-6D [22,23]
The SF-36, currently in its second version, includes 36 self-report
questions regarding functional health and well-being. Participant
responses can be converted to a single index by using preference
weights elicited against SF-36–derived health states. For example,
scores are commonly converted to SF-6D health state utility
values by using valuations elicited from a representative sample
of the UK general population [23]. Scores on the SF-6D can range
from 0.3 to 1.0, where 0.3 indicates the worst health state and 1.0
the best health state.
Data Analyses
The rigor of the mapping approach rests on there being a
considerable overlap between the descriptive systems of the
‘‘starting’’ measure and the ‘‘target’’ measure [19]. The overlap
between the MSIS-29 and the EQ-5D and between the MSIS-29
and the SF-6D would be expected to be substantial as each of the
measures assesses HRQOL. A diagrammatic representation of the
areas of joint coverage is given in Fig. 1.
Statistical conventions in the mapping literature [19] were
followed to examine the relationships between the MSIS-29 and
the EQ-5D index and between the MSIS-29 and the SF-6D. For the
EQ-5D, baseline data from SWIMS were used as the estimation
sample to develop the most appropriate statistical models and to
test within-sample predictive performance. The predictive accu-
racy of the best performing subscale scores and item scores
models was then assessed by using longitudinal data from
MSIS-29 sub-scale
Physical Psychological
EQ-5D dimension
Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depression
SF-6D dimension
Physical functioning
Role limitation
Social functioning
Bodily pain
Mental health
Vitality
Potential areas of overlap
Fig. 1 – Overlap between the descriptive systems of the
MSIS-29 and the EQ-5D/SF-6D. EQ-5D, EuroQol five-
dimension; MSIS-29, the 29-item Multiple Sclerosis Impact
Scale; SF-6D, six-dimension health state short form
(derived from short form 36 health survey).
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baseline are MSIS-29 and SF-36 data collected at the same time.
In follow-up questionnaires, SF-36 and MSIS-29 questionnaires
are used in alternating six-monthly data collection. Therefore,
the analysis here of the SF-6D data uses only baseline data, with
a random sample of 75% of the SWIMS baseline data used for
estimating SF-6D algorithms (the estimation sample) and 25% of
the SWIMS baseline data used for assessing their predictive
accuracy (the validation sample) [30].
Six regression models were estimated for both of the EQ-5D
and the SF-6D.
The EQ-5D index/SF-6D scores were regressed onto the
following:1. Physical and psychological impact scale scores of the
MSIS-29 (model A);
2. Physical and psychological impact scale scores of the
MSIS-29 and their squared terms (model B);
3. Impact scale scores of the MSIS-29 and their interaction
term (model C);
4. Impact scale scores of the MSIS-29 and participant age and
gender (model D);
5. MSIS-29 item scores (model E);
6. MSIS-29 item scores and participant age and gender
(model F).
Multicollinearity of the MSIS-29 items was assessed by using
the ‘‘collin’’ command in STATA. As a result, items 2, 4, 7, 9, 10, 17,
20, 21, 22, 23, 24, 26, 27, and 28 were included in the items
analyses (models E and F). The items that were not statistically
significant were then removed from the models.
Ordinary least squares (OLS) regression models were used for
estimation as OLS has been used in the majority of mapping
studies, with the suggestion that more complex models may not
add predictive power or reduce errors in prediction [31]. Con-
cerns, however, have been raised about the use of OLS, for
example, in underestimating variance in individual predicted
scores [32] and, in a practical context, in underestimating QALY
gains [33]. Therefore, Tobit models [34] and the censored least
adjusted deviation (CLAD) method of estimation [35] were also
used to test their value in further reducing estimation errors.
Tobit models have been used for modeling health state value data
as an upper censoring limit of 1 can be defined [36,37]. This islikely to be particularly applicable to EQ-5D data, which are
known to exhibit ceiling effects [38,39], but may aid the estima-
tion of SF-6D scores, which also have an upper limit of (or are
censored at) 1. However, Tobit models are sensitive to violations
of hetereoscedasticity or nonnormality [36], and CLAD has
become popular in the mapping literature as it is thought to be
robust to such violations [40–42].
When mapping, the principal aim is not to produce a model
that explains the most variance in the data (adjusted R2) but to
derive an algorithm that as accurately as possible estimates
health state utility values at a group level [43]. Therefore, for
each of the regression models (36 in total), estimation errors [19],
in the form of mean absolute error (MAE) and root mean square
error (RMSE), were assessed. MAE is the mean of the absolute
estimation errors across individuals (the estimation error is
the difference between the actual EQ-5D/SF-6D score for a
particular individual and their estimated EQ-5D/SF-6D score
based on the mapping model). RMSE is the positive square root
of the mean squared estimation error. There are currently no
guidelines as to when estimation errors are and are not accep-
table [44], but a systematic review of mapping studies [19] has
reported MAEs from 0.0011 to 0.19 and RMSEs from 0.084 to 0.2.
(Adjusted R2 values of 0.17–0.51 have also been reported.)
Versteegh et al. [44] highlight that MAE and RMSE are not
comparable for models that map to different preference-based
measures, as a larger scale size usually leads to larger error
figures. For example, estimation errors might be expected to be
greater on the EQ-5D than on the SF-6D as the former is on a
scale from  0.594 to 1 and the latter on a scale from 0.3 to 1.
As such, normalized RMSEs [45] were calculated here, which
give RMSE as a percentage of the preference-based measure
scale size.
Also assessed were the proportions of estimates that fell
within 0.05, 0.10, and 0.25 of the actual EQ-5D/SF-6D value.
The predictive accuracy of the algorithms with the lowest
prediction errors was then assessed. The actual EQ-5D scores
were compared with the estimated scores at a number of follow-
up points in the SWIMS data, and the actual SF-6D scores were
compared with the estimated scores in the validation sample at
baseline. Prediction errors were also assessed according to
differing severities of EQ-5D/SF-6D health states.
Data analysis was conducted in STATA 10.Results
EQ-5D
Predictive performance (estimation sample)
A total of 672 of the 827 (81.3%) SWIMS participants gave
complete EQ-5D and MSIS-29 v2 data at baseline. Their demo-
graphic and clinical characteristics are shown in Table 1. EQ-5D
scores ranged from  0.429 to 1 and were bimodally distributed
with a mean 7 SD of 0.6127 0.288. The correlations between the
physical impact scale and EQ-5D scores and the psychological
impact scale and EQ-5D scores were  0.708 and  0.492,
respectively (both significant at P o 0.001).
The 18 models performed broadly similarly in predicting EQ-
5D health state utility values from the MSIS-29 data. The OLS
models performed the best, followed by the Tobit models, and the
CLAD method of estimation performed least well (see Appendix 1
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2012.07.007). The OLS model using subscale scores and
participant age and gender (model D) performed best, with
marginally lower prediction errors (MAE 0.147; % RMSE 12.5).
Demographic information, however, may not be available to
those wishing to use a conversion algorithm, and so the OLS
Table 1 – Demographic and clinical characteristics of the
estimation samples.
Characteristic EQ-5D
sample
(n ¼ 672)
SF-6D
sample
(n ¼ 495)
MS diagnosis, n (%)
Relapsing-remitting 290 (43.2) 218 (44.0)
Primary progressive 120 (17.9) 85 (17.2)
Secondary progressive 106 (15.8) 77 (15.6)
Benign 26 (3.9) 21 (4.2)
Combination 32 (4.8) 23 (4.6)
Not known 98 (14.9) 71 (14.3)
Gender, n (%)
Male 173 (25.8) 131 (26.5)
Female 497 (74.2) 363 (73.5)
Age (y), mean 7 SD 49.5 7 11.4 49.2 7 11.3
(range) (19 to 79) (19 to 78)
MSIS-29 physical impact
scale score, mean 7 SD
43.70 7 16.00 44.65 7 16.11
(range) (20 to 80) (20 to 80)
MSIS-29 psychological
impact scale score,
mean 7 SD
18.41 7 6.40) 18.71 7 6.44)
(range) (9 to 36) (9 to 36)
EQ-5D index score,
mean 7 SD
0.612 7 0.288 –
(range) (  0.429 to 1) –
SF-6D score, mean 7 SD – 0.637 7 0.133
(range) – (0.301 to 1)
EQ-5D, EuroQol five-dimension; MS, multiple sclerosis; MSIS-29,
the 29-item Multiple Sclerosis Impact Scale; SF-6D, six-dimen-
sional health state short form (derived from short form 36 health
survey).
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RMSE 12.7) was also assessed for predictive accuracy. In addition,
the best performing algorithm based on item scores (OLS model
F: MAE 0.147; % RMSE 12.7) and the items model without the
inclusion of age and gender (OLS model E: MAE 0.149; % RMSE 12.
9) were also tested for predictive accuracy.Fig. 2 – Mean absolute errors by EQ-5D health state severity
in the longitudinal sample. CI, confidence interval; EQ-5D,
EuroQol five-dimension; OLS, ordinary least squares.Predictive accuracy (longitudinal data)
The validation sample comprised SWIMS follow-up data across
10 time points, based on participants who provided complete
MSIS-29 and EQ-5D data (responses ¼ 2461). The estimated EQ-
5D scores, as compared with the actual scores for each of the OLS
models, at each of the time points are given in Table 2. These data
show the similarity of the estimated and actual mean EQ-5D
scores. The models performed well at estimating scores up to 3
years post-baseline, after which there was generally a slight
increase in error.
The errors in the longitudinal sample for each of the models
tested for predictive accuracy are given in Appendix 1 in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2012.07.
007 and in Fig. 2 by differing degrees of health state severity. The
errors for the OLS models using subscale scores (model B: MAE 0.
162, % RMSE 13.6; model D: MAE 0.164, % RMSE 13.6) were less
than the errors for the models that used item scores (model E:
MAE 0.167, % RMSE 13.8; model F: MAE 0.167, % RMSE 13.7).For the four models assessed for predictive accuracy, prediction
errors reduced incrementally as the EQ-5D scores increased; that
is, predictions consistently improved as health state utility values
improved (Fig. 2).
The details of the best performing subscale scores and item
scores algorithms are given in Tables 3 and 4.
SF-6D
A total of 660 of the 819 (80.6%) SWIMS participants fully completed
both the MSIS-29 v2 and the SF-36 v2 at baseline. Four hundred
and ninety-five individuals were randomly assigned to the estima-
tion sample and 165 to the validation sample.
Predictive performance (estimation sample)
The demographic and clinical characteristics of the estimation
sample are given in Table 1. SF-6D scores ranged from 0.301 to 1,
with a mean 7 SD of 0.637 7 0.133. The correlation between SF-
6D and physical impact scale scores was  0.760, and the
correlation between SF-6D and psychological impact scale scores
was  0.668 (both significant at P o 0.001).
The 18 models performed comparably in predicting SF-6D
scores (see Appendix 2 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2012.07.007). The Tobit models and the
CLAD method of estimation offered no advantage in terms of
estimation errors over the OLS models. The OLS model based on
MSIS-29 subscale scores and subscale scores squared (model B)
was the most accurate in its estimations (MAE 0.058; % RMSE 10.
3). The OLS model (F) based on MSIS-29 item scores and
participant demographics (MAE 0.064; % RMSE 11.4) and the
OLS items model without the inclusion of age and gender (model
E: MAE 0.064; % RMSE 11.6) were also tested for predictive
accuracy.
Predictive accuracy (validation sample)
The validation sample comprised the remaining 25% of the
SWIMS participants who provided complete MSIS-29 v2 and SF-
36 data at baseline (n ¼ 165). Their mean 7 SD physical impact
scale and psychological impact scale scores were 41.557 15.27
Table 2 – Mean EQ-5D and SF-6D estimated test sample scores, by model, as compared with actual scores.
Follow-up
time point
n Actual mean
score
Estimated mean score
OLS B—
Subscales and
subscales squared
OLS D—
Subscales and
demographics
OLS E—
Item scores
OLS F—
Item scores and
demographics
EQ-5D
6 months 417 0.578 0.576 0.573 0.563 0.565
12 months 378 0.600 0.589 0.582 0.582 0.580
18 months 340 0.569 0.572 0.566 0.561 0.561
24 months 340 0.565 0.580 0.571 0.576 0.571
30 months 259 0.556 0.548 0.543 0.542 0.543
36 months 236 0.604 0.590 0.582 0.584 0.582
42 months 192 0.495 0.549 0.544 0.544 0.544
48 months 169 0.566 0.589 0.581 0.584 0.581
52 months 82 0.456 0.519 0.517 0.513 0.518
60 months 48 0.578 0.580 0.573 0.583 0.582
All time points 2461 responses 0.567 0.573 0.567 0.566 0.565
SF-6D
Baseline 165 0.639 0.658 0.656 0.658
EQ-5D, EuroQol five-dimension; OLS, ordinary least squares; SF-6D, six-dimension health state short form (derived from short form 36 health
survey).
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was 0.6397 0.128. The estimated SF-6D scores, as compared with
the actual scores for each of the models, are given in Table 2.
Prediction errors in the validation sample for all the models
tested are given in Appendix 2 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2012.07.007. These were very
similar to those found in the estimation sample, particularly for
the OLS subscales and subscales squared model (model B: MAE 0.
059; % RMSE 10.4%). There was no added value in terms of
prediction errors in using an items model (model E: MAE 0.068,
% RMSE 12.1; model F: MAE 0.067, % RMSE 12.0). For the three
models assessed for predictive accuracy, the prediction errors
were slightly higher when estimating the poorer SF-6D health
states as compared with the better SF-6D health states (Fig. 3),
but this was not as apparent as when EQ-5D scores were
estimated. Details of the best performing subscale scores and
item scores algorithms are given in Tables 3 and 4.Fig. 3 – Mean absolute errors by SF-6D health state severity
in the validation sample CI, confidence interval; OLS,
ordinary least squares; SF-6D, six-dimension health state
short form (derived from short form 36 health survey).Conclusions
This article gives a method by which health state utility values
can be estimated (or mapped) from scores on the MSIS-29,
enabling assessment of the cost-effectiveness, and the broader
impact, of treatments for people with MS. The algorithms pre-
sented can be applied to MSIS-29 v2 subscale scores and/or item
scores, for estimating both EQ-5D and SF-6D health state utility
values. These algorithms compare well, in statistical terms, to
other published mapping studies [19]. They are applicable to
broad populations of people with MS as the SWIMS sample that
they were derived from was heterogeneous, as shown by the
wide range of ages, MS subtypes, and EQ-5D, SF-6D, and MSIS-29
scores, and there was a high proportion of complete MSIS-29 and
EQ-5D (81.3%) and SF-6D (80.6%) responses given by the cohort.
This research sits against a backdrop of very little mapping
relating to neurological conditions. One study has mapped from the
Parkinson’s Disease Questionnaire [41] and, more recently, Versteegh
et al. [44] have provided algorithms to estimate EQ-5D scores from
version 1 of the MSIS-29. The current study provides a useful
complement to this work for the revised version of thequestionnaire; analogous methods have been used in the generation
of algorithms, and the resulting estimation errors are very similar
(for MAE, RMSE, and normalized RMSE). In addition, algorithms are
presented in the current study for the SF-6D as well as for the EQ-5D.
Results show that models predict well for both the SF-6D and
the EQ-5D. The models, however, worked better at estimating SF-
6D, rather than EQ-5D, health state utility values as the prediction
errors (normalized RMSE) for the SF-6D were consistently lower.
The greater success of the SF-6D models is likely to be explained
by two factors: 1) the more normal distribution of SF-6D scores
(and its compressed scale) as compared with the bimodal
distribution of EQ-5D scores, making the SF-6D more amenable
Table 3 – Predictive performance of best performing MSIS-29 sub-scale scores and item scores (OLS) models.
EQ-5D SF-6D
Estimation samples (EQ-5D: n ¼ 672; SF-6D: n ¼ 495)
Model B—Subscale
scores & subscale
scores squared
Model F—Item
scores, age & gender
Model B—Subscale
scores & subscale
scores squared
Model F—Item
scores, age & gender
Regression coefficients:
MSIS-29 physical sub-scale  0.0078471† –  0.0096719y –
MSIS-29 psychological sub-scale  0.0127284 –  0.0251063y –
Physical sub-scale squared  0.0000405 – 0.0000556y –
Psychological sub-scale squared 0.000201 – 0.0004559y –
MSIS-29 item 2 –  0.0487625y –  0.0099726†
MSIS-29 item 4 –  0.0311409z –  0.0147913z
MSIS-29 item 7 –  0.0368637y –  0.0203136y
MSIS-29 item 9 –  0.0340509z –  0.010971†
MSIS-29 item 10 –  0.0256986† –  0.0084575
MSIS-29 item 17 –  0.0480758y –  0.0145158z
MSIS-29 item 21 –  0.0308195z –  0.0240376y
MSIS-29 item 23 – – –  0.0269404y
MSIS-29 item 24 –  0.029123z – –
MSIS-29 item 27 – – –  0.0089197
MSIS-29 item 28 – – –  0.0120671z
Age –  0.0034471y –  0.001259y
Gender –  0.000527 –  0.0015292
Constant 1.200546 1.350287 1.23472 1.023371
Predictive performance:
Adjusted R2 0.5063 0.4979 0.6920 0.6301
MAE (95% CI) 0.147 (0.136–0.157) 0.156 (0.145–0.166) 0.058 (0.054–0.062) 0.064 (0.059–0.068)
RMSE (normalized for range) 0.202 (12.7%) 0.208 (13.0%) 0.073 (10.3%) 0.080 (11.4%)
Estimates within 7 0.05 of true value (%) 25.2 25.4 51.1 47.0
Estimates within 7 0.1 of true value (%) 50.9 43.3 81.8 78.7
Estimates within 7 0.25 of true value (%) 80.7 82.0 100.0 99.8
Validation samples (EQ-5D: n responses ¼ 2461; SF-6D: n ¼ 165)
Predictive performance:
MAE (95% CI) 0.162 (0.156–0.167) 0.167 (0.161–0.172) 0.059 (0.052–0.07) 0.067 (0.059–0.075)
RMSE (normalized for range) 0.217 (13.6%) 0.219 (13.7%) 0.074 (10.4%) 0.084 (12.0%)
Estimates within 7 0.05 of true value (%) 22.5 21.1 52.7 42.1
Estimates within 7 0.10 of true value (%) 44.6 40.4 81.2 77.4
Estimates within 7 0.25 of true value (%) 77.7 77.7 100.0 100.0
CI, confidence interval; EQ-5D, EuroQol five-dimension; MAE, mean absolute error; MSIS-29, the 29-item Multiple Sclerosis Impact Scale; OLS,
ordinary least squares; RMSE, root mean square error; SF-6D, six-dimension health state short form (derived from short form 36 health
survey).
* Only statistically significant items were retained in the model.
† Po 0.05.
z Po 0.01.
y Po 0.001.
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 8 4 – 1 0 9 1 1089for use in regression analyses, and 2) the greater overlap in
content between the SF-6D and the MSIS-29, as compared with
the overlap between the EQ-5D and the MSIS-29. This is shown in
Figure 1 and also by the higher correlations, particularly for the
psychological impact scale. (The SF-6D is derived from the SF-36,
which has a specific mental component subscale.) The algo-
rithms overpredicted EQ-5D values when estimating for the more
severe health states (Fig. 2), a common finding in mapping
studies [43], but this was not marked when estimating SF-6D
values. In an attempt to ameliorate the overpredictions found
with the EQ-5D, we used a variety of two-part regression models,
as suggested in the literature, for example, [30,44]. These did not
improve the errors found. However, in the context of economic
evaluations, comparisons are primarily made across groups and
individual predictions are less important than the effect of
prediction errors at the group level [43]. Only 6% of the sample
here had scores below 0.04 (the minimum score predicted by the
best performing EQ-5D model), meaning that these errors mayhave little impact on the comparison of health state utility values
at a group level, in a policy context, particularly in specific
evaluation settings where the target group is in the mild-to-
moderate spectrum of disease severity.
The appropriateness of using mapping, and the validity of the
resulting algorithms, rests on there being significant overlap in
the content of the measures being mapped [19]. Information is,
inevitably, lost in the conversion process, and less similarity
between the scales increases the theoretical uncertainty of what
is retained by the resulting conversion function [46]. This being
said, there is a high degree of overlap and correlation between
the MSIS-29 v2 and the EQ-5D and between the MSIS-29 and the
SF-6D. In addition, the issue of theoretical uncertainty may well be
an academic consideration in the practical context of using mapped
data. If health state utility values can be accurately estimated from
scores on the non–preference-based measure (as is the case with
the MSIS-29 and the EQ-5D/SF-6D), the nature of what is lost in the
mapping algorithm may receive limited attention.
Table 4 – Best performing EQ-5D and SF-6D subscale scores and item scores models.
Model Estimated EQ-5D score
OLS subscale scores and subscale scores
squared model (B)
¼ 1.200546 – (0.0078471  PhIS) – (0.0127284  PsIS) – (0.0000405  PhIS  PhIS) þ (0.000201
 PsIS  PsIS)
OLS items and demographics model (F) ¼ 1.350287  (0.0487625  item 2)  (0.0311409  item 4)  (0.0368637  item 7)
 (0.0340509  item 9)  (0.0256986  item 10)  (0.0480758  item 17)  (0.0308195
 item 21)  (0.029123  item 24)  (0.0034471  age)  (0.000527  gender)
Model Estimated SF-6D score
OLS subscale scores and subscale scores
squared model (B)
¼ 1.23472 – (0.0096719  PhIS) – (0.0251063  PsIS) þ (0.0000556  PhIS  PhIS) þ (0.0004559
 PsIS  PsIS)
OLS items and demographics model (F) ¼ 1.023371  (0.0099726  item 2)  (0.0147913  item 4)  (0.0203136  item 7)
 (0.010971  item 9)  (0.0084575  item 10)  (0.0145158  item 17)  (0.0240376
 item 21)  (0.0269404  item 23)  (0.0089197  item 27)  (0.0120671  item 28)
 (0.001259  age)  (0.0015292  gender)
Note. Gender was coded ‘‘male’’ ¼ 0, ‘‘female’’ ¼ 1.
EQ-5D, EuroQol five-dimension; MSIS-29, the 29-item Multiple Sclerosis Impact Scale; OLS, ordinary least squares; PhIS, MSIS-29 Physical
impact scale score; PsIS, MSIS-29 Psychological impact scale score; SF-6D, six-dimension health state short form (derived from short form 36
health survey).
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 8 4 – 1 0 9 11090The findings presented here have demonstrated that it is
possible to estimate health state utility values for two of the most
commonly used preference-based measures, the EQ-5D and the
SF-6D, from individual participant scores on the MSIS-29 v2.
Further research is needed to consider how the mapping algo-
rithms derived here perform in practical policy contexts when
compared with observed EQ-5D and SF-6D values. The algorithms
can provide broadly applicable information about the HRQOL of
people affected by MS and inform the framework for assessing
the cost-effectiveness of new and existing treatments for MS.
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